Company
Investment-firm
Last deal
Amount
Stage
Date
all rounds
Total amount
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
Contacts
location
Contact Email
Website URL
Similar Companies586
RiverVest
RiverVest is a venture capital firm that identifies and incubates promising early-stage life science companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Bioventures Investors
Bioventures Investors is a private equity firm that invests in life sciences and healthcare companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
H.I.G. BioHealth Partners
H.I.G. BioHealth Partners is a Miami-based venture capital firm.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Grampian Biopartners
Grampian Biopartners is an angel investment group that specialises in seed funding early stage life-science companies.
Sector
Subsector
Location
count Of Investments
Financials
Funding Rounds1
Number of Funding Rounds
Money Raised
Their latest funding was raised on 13.09.2022. Their latest round Grant
Investments173
Vittoria Biotherapeutics
Vittoria Biotherapeutics is a cutting-edge gene-edited cell therapeutics company.
Sector
Subsector
Location
total rounds
total raised
KayoThera
KayoThera develops therapeutics to cure late-stage and metastatic cancers.
Sector
Subsector
Keywords
Location
total rounds
total raised
Palvella Therapeutics
Palvella Therapeutics is a start-up life sciences company that develops therapies for abandoned patient populations.
Sector
Subsector
Location
total rounds
total raised
Co-Investors
Exits13
SansRosa Pharmaceuticals
Sansrosa Pharmaceutical Development is a company that focuses on developing dermatological products specifically for treating rosacea.
Sector
Subsector
Keywords
Location
total rounds
total raised
Gelifex
Gelifex is a medical company specialising in disc implants for degenerative disc disease.
Sector
Subsector
Keywords
Location
total rounds
LumenVu
Philadelphia-based development stage company LumenVu, Inc.
Sector
Subsector
Location
total rounds
People
Founders2
Gregory Harriman
Greg is the president of Main Line Ventures, an investment and consultancy company offering funding, technical expertise, and executive management experience to entrepreneurs and early stage bioscience and healthcare companies in the Mid-Atlantic region. Greg is an accomplished executive with over 20 years of experience with increasing responsibilities in academic medicine and biopharmaceutical companies. He received his medical degree from the University of California, San Diego and trained at Washington University in St. Louis, MO and the National Institutes of Health in Bethesda, MD. He is board-certified in internal medicine, infectious diseases, and clinical & laboratory immunology. He previously had a successful academic career at the NIH and Baylor College of Medicine, having published over 40 articles and book chapters, receiving NIH and private foundation grant funding, and performing innovative, significant research in immunology, vaccines, and immune-mediated diseases. He is a fellow of the American College of Physicians and is a member of several other professional medical organizations, including the American Academy of Asthma, Allergy & Immunology. He has held leadership positions in several small and large biopharmaceutical companies having global experience in the successful research and development of pharmaceuticals, biologics, medical devices and cell therapies, including a multi-billion dollar product for treatment of immune-related diseases.
current job
Gregory Harriman
Barbara S. Schilberg
Ms. Schilberg has more than 30 years of experience working with academic technologies and start-up companies in the life sciences sector. Under her leadership as CEO, BioAdvance has committed $24.2 million to 36 seed-stage companies and 21 pre-seed projects focusing in areas including Alzheimer's disease, cancer, diabetes, obesity and infectious diseases. The BioAdvance portfolio companies have leveraged $1.6 billion in subsequent capital from venture capital, grants, collaborations, M&A activity and product revenues. Eight portfolio companies have been acquired, one company has completed an initial public offering, and one exited through a refinancing. Ms. Schilberg is a board member or serves as an observer on the boards of several BioAdvance portfolio companies including Immunome, Jenrin Discovery, Melior Pharmaceuticals, Novira Pharmaceuticals and QR Pharma. As a senior executive with four emerging life sciences companies, Ms. Schilberg's prior experience provides significant insight into the key elements needed to build successful companies including public and private financings, intellectual property protection, corporate partnering arrangements and the management of research programs. She joined Cephalon in 1994 as Senior Vice President and General Counsel and as a member of the executive committee. As part of her responsibilities, she led a multi-disciplinary team charged with completing Phase III clinical trials and preparing a new drug application for PROVIGIL® (modafinil), which was approved by the FDA in December 1999. She joined Incara Pharmaceuticals in 1998 as Executive Vice President and General Counsel, where she managed a research operation in Princeton, NJ engaged in discovering new antibacterial therapeutics. She continued in that capacity after the operation's acquisition by Advanced Medicine (now Theravance) in 2000. Ms. Schilberg also served as Vice President and General Counsel at Locus Discovery, Inc., an emerging pharmaceutical company in Blue Bell, PA engaged in computational drug design. Before joining industry, Ms. Schilberg specialized in representing biopharmaceutical companies and research institutions in the commercialization of technology, as a partner in the Philadelphia office of Morgan, Lewis & Bockius. Ms. Schilberg received a J.D. from the University of Virginia and clerked with the Honorable Edward R. Becker, now Senior Judge of the U.S. Court of Appeals for the Third Circuit.
current job
Barbara S. Schilberg
Employee Profiles15
Jeff Edelson
Entrepreneur in Residence / Scientific Liason